- Home
- RMCO vs IGC Comparison
RMCO vs IGC Comparison
Compare RMCO & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCO
- IGC
- Stock Information
- Founded
- RMCO 2021
- IGC 2005
- Country
- RMCO United States
- IGC United States
- Employees
- RMCO N/A
- IGC N/A
- Industry
- RMCO Multi-Sector Companies
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- RMCO Miscellaneous
- IGC Health Care
- Exchange
- RMCO Nasdaq
- IGC Nasdaq
- Market Cap
- RMCO 45.7M
- IGC 39.8M
- IPO Year
- RMCO N/A
- IGC N/A
- Fundamental
- Price
- RMCO $3.04
- IGC $0.41
- Analyst Decision
- RMCO Buy
- IGC Strong Buy
- Analyst Count
- RMCO 1
- IGC 2
- Target Price
- RMCO N/A
- IGC $4.00
- AVG Volume (30 Days)
- RMCO 165.1K
- IGC 869.4K
- Earning Date
- RMCO 11-14-2025
- IGC 11-11-2025
- Dividend Yield
- RMCO 0.32%
- IGC N/A
- EPS Growth
- RMCO N/A
- IGC N/A
- EPS
- RMCO N/A
- IGC N/A
- Revenue
- RMCO $2,641,171.00
- IGC $1,327,000.00
- Revenue This Year
- RMCO N/A
- IGC $3.54
- Revenue Next Year
- RMCO N/A
- IGC $15.12
- P/E Ratio
- RMCO N/A
- IGC N/A
- Revenue Growth
- RMCO 292.46
- IGC 24.95
- 52 Week Low
- RMCO $0.90
- IGC $0.25
- 52 Week High
- RMCO $4.76
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- RMCO 53.92
- IGC 54.39
- Support Level
- RMCO $2.80
- IGC $0.36
- Resistance Level
- RMCO $4.29
- IGC $0.43
- Average True Range (ATR)
- RMCO 0.52
- IGC 0.02
- MACD
- RMCO -0.05
- IGC -0.00
- Stochastic Oscillator
- RMCO 14.29
- IGC 71.08
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.